Islet-brain1 (IB1) or c-Jun NH2 terminal kinase interacting protein-1 (JIP-1), the product of the MAPK8IP1 gene, functions as a neuronal scaffold protein to allow signalling specificity. IB1/ JIP-1 interacts with many cellular components including the reelin receptor ApoER2, the lowdensity lipoprotein receptor-related protein (LRP), kinesin and the Alzheimer's amyloid precursor protein. Coexpression of IB1/JIP-1 with other components of the c-Jun NH2 terminal-kinase (JNK) pathway activates the JNK activity; conversely, selective disruption of IB1/JIP-1 in mice reduces the stress-induced apoptosis of neuronal cells. We therefore hypothesized that IB1/JIP-1 is a risk factor for Alzheimer's disease (AD). By immunocytochemistry, we first colocalized the presence of IB1/JIP-1 with JNK and phosphorylated tau in neurofibrillary tangles. We next identified a À499A4G polymorphism in the 5' regulatory region of the MAPK8IP1 gene. In two separate French populations the À499A4G polymorphism of MAPK8IP1 was not associated with an increased risk to AD. However, when stratified on the þ 766C4T polymorphism of exon 3 of the LRP gene, the IB1/JIP-1 polymorphism was strongly associated with AD in subjects bearing the CC genotype in the LRP gene. The functional consequences of the -499A4G polymorphism of MAPK8IP1 was investigated in vitro. In neuronal cells, the G allele increased transcriptional activity and was associated with an enhanced binding activity. Taken together, these data indicate that the increased transcriptional activity in the presence of the G allele of MAPK8IP1 is a risk factor to the onset of in patients bearing the CC genotype of the LRP gene.
Introduction
Mitogen-activated protein kinases (MAPKs) are key enzymes involved in diverse cellular processes in response to extracellular stimuli. They regulate cell survival, cell death, proliferation and/or differentiation. [1] [2] [3] Generally, activation of the ERK forms of MAPK causes survival responses, whereas activation of the p38 and c-Jun NH2-terminal kinase (JNK) promotes cell death. In response to various stimuli, specific MAPK kinase kinases such as MLK1 and MKK7 are activated and sequentially phosphorylate the JNK kinase. Once activated, JNK phosphorylates c-Jun, which in turn modulates the expression of many target genes. [1] [2] [3] The action specificity of JNK requires the presence of a scaffold protein termed c-Jun NH2-terminal kinase interacting protein-1 (JIP-1). 4 JIP-1 was initially cloned from a mouse library using JNK as a bait in a two-hybrid system. 5 The rat and human homologue of JIP-1 was independently identified and termed Isletbrain1 (IB1), because its expression is restricted to insulin-secreting b-cells of the pancreas and neurons. 6, 7 The function of IB1/JIP-1 is critical to mediate the JNK signal transduction. Coexpression of IB1/JIP-1 with components of the JNK pathway enhances the activation of JNK. 8 However, isolated overexpression of IB1/JIP-1 inhibits the JNK signal transduction probably by sequestering the components of the pathway into separate complexes, therefore inhibiting signalling. 4, 5, 9, 10 The gene encoding IB1/JIP-1 has been invalidated in mice. Disruption of IB1/JIP-1 prevented the JNK activation induced by exposure to excitotoxic or anoxic stress, thus leading to a decreased apoptosis of hippocampal neuronal cells. 11 In another mice strain, the selective disruption of the gene encoding IB1/JIP-1 was associated with early embryological cell death indicating that IB1/JIP-1 is required during early cell division. 12 IB1/JIP-1 contains an SH3 and a phosphotyrosine-interacting protein domain (PID) in the COOH-terminal part of the protein which interact with p190 RhoGEF, the reelin receptor ApoER2, the low-density lipoprotein receptor-related protein (LRP), megalin, kinesin and the Alzheimer's amyloid precursor protein (APP). [13] [14] [15] [16] [17] [18] Structurally, IB1/JIP-1 is related to FE65 by the presence of a PID domain. 6 IB1/ JIP-1 interacts with several critical cellular partners involved in neuronal cell function or development. As an example, LRP and ApoER2 interact with IB1/ JIP1 13, 14 . In human, polymorphisms within the LRP and FE65 genes were described as risk factors to Alzheimer's disease (AD) [19] [20] [21] [22] [23] [24] . Since IB1/JIP-1 is related to FE65 and interacts with several cellular partners that are critical for neuronal cell function and/or have been associated with human AD, we hypothesized that abnormal expression or function of the IB1/JIP-1 protein could contribute to the pathogenesis of neurodegenerative diseases such as AD.
As mentioned, IB1/JIP-1 is expressed in neuronal cells in particular in the hippocampus, the cortex and the cerebellum. 25 In vivo, following a transient middle cerebral occlusion, the expression of IB1/JIP-1 and JNK is enhanced 8 h during reperfusion. 26 It has been also reported that JNK activation is increased following transient global focal ischaemia, in particular in the CA1 neurons of the hippocampus. 27 In other cell systems, IB1/JIP-1 was shown to be downregulated once cells were exposed to various stresses such as UV, cytokines, parietal stress or starving 10, 28 . As a consequence, JNK activity is increased and the cells undergo a pro-apoptotic pathway. 28 Conversely, overexpression of IB1/JIP-1 or the use of small JNK-inhibitory peptides could prevent the proapoptotic signalling cascade. [29] [30] [31] In humans, a single missense mutation was identified in the coding region of the MAPK8IP1 gene. 32 This mutation is associated with a rare form of late-onset, monogenic form of type II diabetes and in vitro an accelerated apoptosis of the insulin-secreting cells. 32 Herein, we describe the identification of a -499A4 G polymorphism in the promoter region of the human MAPK8IP1 gene encoding IB1/JIP-1. We identified its functional role in neuronal cells and evaluated whether it could be associated with AD in two different case-control studies involving French Caucasians.
Subjects, material and methods

Study 1
The population consisted of subjects from the ELDNOR study selected on cognitive status. 33 Two groups with highly contrasted levels of cognitive functions were selected from the ELDNOR population: a group of demented individuals (n ¼ 230) including all ELDNOR subjects with an MMSE score less than 10 and/or a diagnosis of dementia according to criteria given in the Diagnostic and Statistical Manual of Mental Disorders, 3rd edn., revised (DSM-III-R), and a group of controls (n ¼ 250) including all ELDNOR subjects with an MMSEX25 and without any symptom of dementia. This population can be divided according to the type of dementia defined by the International Classification of Disease Release 9 (ICD9). Among the demented subjects, 71 suffered from AD. Due to the low number of AD cases in the ELDNOR population, we added European Caucasian patients (n ¼ 172) recruited in France, UK, Netherlands, Spain and Italy. All patients were thoroughly investigated clinically. The diagnosis of AD was made according to the DSM-III-R and the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria. Although diagnostic criteria differed, there was no difference in genotype distribution between the two groups of AD patients.
Study 2
Between June 1995 and March 1996, 127 cases of dementia were recruited in the long-term care department of gerontology of the hospital of Limeil Brévannes (France). All the subjects received an oral description of the study and gave an informed consent. For those who were mentally incompetent, we approached their next of kin to sign an informed consent. Dementia was identified according to DSM-III-R criteria. Cases were classified in to two groups: AD patients (n ¼ 56) were selected as subjects with criteria of probable AD given by NINCDS-ADRDA. 34 Others were classified as non-AD (n ¼ 71).
A total of 185 brains coming from routine autopsies carried out at the Hospices Civils de Strasbourg (Eastern France) were used as controls for this study. Recruitment was designed in order to exclude dementia cases and patients suffering from neurological pathologies. Individuals were not recruited from medical institutions in which a majority of patients present dementia but from a general hospital. Most of the cases were admitted less than 48 h before the death in emergency services and were living at home prior to their admission. In order to ensure the exclusion of AD-affected cases, neuropathological criteria were also applied to exclude Braak stage V individuals from the control group. 35 All studies were approved by the Ethics Committee of the Lille University Hospital.
Genetic study
For each participant, genomic DNA was prepared either from white blood cells using a salt-out procedure or from brains using phenol-chloroform. Mutation screening of the 12 exons of the MAPK8IP1 was performed by direct sequencing. 32 In addition, 750 bp upstream the ATG position was screened in 46 0 (reverse). The PCR conditions were 941C, 1 min; 581C, 1 min; and 721C, 1 min for 30 cycles, and final extension at 721C for 10 min. These primers gave a PCR product of 427 bp. The MAPK8IP1 polymorphism was detected using allele-specific oligonucleotides hybridization with the following primers: 5 0 -CCTGTACACTTTAAG-3 0 for the wild-type allele and 5 0 -CCTGTACGCTTTAAG-3 0 for the mutated allele (polymorphism underlined). Membranes were hybridized at 371C for 1 h, washed twice in 1 Â SSC, 10% SDS buffer for 5 min, washed in 0.5 Â SSC, 10% SDS buffer for 5 min, and washed in 0.5 Â SSC, 10% SDS buffer at 381C for 3 min. The C766T polymorphism in the exon 3 of the LRP gene was genotyped as previously described. 24 The laboratory personnel was blind to clinical information concerning the subjects tested. Some subjects could not be genotyped for technical reasons.
Cell culture, transfection and luciferase assay The neuroblastoma cell lines LA-N-1 and SK-NB-1 were grown at 371C in the presence of 5% CO 2 in RPMI1640 supplemented with glutamine (Gibco BRL) and 10% fetal calf serum (FCS). The mutated A/G promoter construct (mutIB1) was generated by PCR of the human (À691/ þ 41 bp) promoter fused to the luciferase reporter gene as described. 36 The two constructs were verified by DNA sequencing to confirm the introduction of the desired mutation. Cells were transfected using TransFast Transfection Reagent (Promega) in RPMI1640 medium without FCS. Cells were plated in 12-well plates and grown to 60% confluence. On the day of the transfection, 1 mg of DNA was mixed with 3 ml of Transfast reagent and incubated at room temperature. After 15 min of incubation, plated cells were overlaid with the DNA-Transfast mixture and incubated at 371C for 1 h. To each well, 2 ml of RPMI1640 with serum was added. Cells were incubated for 48 h and harvested with 110 ml of the passive lysis buffer (Promega). Luciferase activities (from IB1WT, mutIB1 and normalization Renilla pRLCMV (pRLCMVrenilla) vectors) were measured with 50 ml of protein extract solution by using the Dual-Luciferase reporter assay system (Promega) and a Turner TD-20/20 Luminometer.
Nuclear extracts and electrophoretic mobility shift assays (EMSA) Nuclear extracts from LA-N-1 cells were prepared as previously described. 36 Sequences of oligonucleotides used in the gel retardation are as follows. For wildtype sequence, sense 5 0 -CCAAACCTGTACACTTTAA-GAGC-3 0 and antisense 5 0 -GGGCTCTTAAAGTGTA-CAGGTTT-3 0 , for mutated sequence, sense 5 0 -CCAAACCTGTACGCTTTAAGAGC-3 0 and antisense 5 0 -GGGCTCTTAAAGCGTACAGGTTT-3 0 . The mutated nucleotide is underlined. Complementary sense and antisense oligonucleotides were hybridized and then filled in by the Klenow fragment of DNA polymerase I (Roche Diagnostics) in the presence of [a 32 P]deoxycytosine triphosphate (Amersham). Free nucleotides were separated by centrifugation through G-50 column. For binding, 5 mg of nuclear proteins were preincubated on ice, in the presence or absence of an excess of unlabelled competitor DNA, for 10 min in 20 ml of a solution containing 25 mM HEPES (pH 7.9), 20% glycerol, 5 mM dithiothreitol, 100 mM KCl and 2 mg of poly(dI-dC). poly(dI-dC). Approximately 100 fmol of double-strand labelled oligonucleotides was mixed with nuclear proteins, and the mixture was incubated for 20 min on ice. Samples were loaded onto a 6% nondenaturing polyacrylamide gel with 1 Â Tris-glycine buffer. The gels were fixed in a solution of 10% acetic acid and 30% methanol, dried and exposed to Hyperfilm-MP (Amersham).
Antibodies
The affinity-purified rabbit anti-IB1/JIP-1 and the monoclonal antibody AD2 that reacts with phosphorylated Ser396 and Ser404 of tau proteins have been described previously. 25, 32, 37, 38 The phosphorylated tau proteins are typically found in AD.
39 AD2 antibody was kindly provided by C Mourton-Gilles.
Immunohistochemistry
Following preincubation in 3% FCS in Tris-buffer (50 mM Tris-HCl, pH 7.4,. 122 mM NaCl), floating vibratome sections, cut in a frontal plane at a thickness of 40 mm, were exposed overnight to primary antibodies, by using the affinity-purified polyclonal antibody at a 1 : 40 dilution and AD2 at a 1 : 2000 dilution. After several rinses with Trisbuffered saline, brain sections were incubated with goat anti-rabbit antibody conjugated with Texas red and goat anti-mouse antibody conjugated with Oregon green at a dilution of 1 : 50 (Molecular Probes). Confocal microscopy (Leica TCS NT) was used to discriminate IB1/JIP-1 and tau staining. Excitation was obtained with an argon-krypton laser, with lines set at 488 nm for Oregon green excitation and 568 nm for Texas red excitation; the emitted light was filtered through appropriate filters (BF 530/30 for Oregon green, LP 590 for Texas red). Images were taken with a 63 objective, NA 1.2. Picture size is between 284 Ko and 1 M-bites. For each field, a digitized series of optical sections at different planes of focus were collected on the host with section planes separated by IB1/JIP-1 and Alzheimer's disease N Helbecque et al 1-2 mm. Care was taken to use the full dynamic range of the photomultipliers by using a special look-up table (glowover-glowunder, Leica). The sections were processed by using the Adobe Photoshop software.
Statistical analysis
For genetic studies, statistical analyses were performed with the SAS software release 6.12. (SAS Institute Inc., Cary, NC, USA). Means and standard deviations were calculated for quantitative data. Categorical data were tested using Pearson's w 2 . Multivariate logistic regression models were used to estimate adjusted odds ratio (OR) and 95% confidence intervals (95% CI). Statistical significance was defined at a value of Po0.05. An interaction between MAPK8IP1 and LRP polymorphisms was systematically looked for. For biological studies, data were expressed as mean 7SEM and were compared using Student's t-test. Statistical significance was defined at a value Po0.05 (*) and Po0.01 (**).
Results
IB1/JIP-1 is colocalized in neurofibrillary tangles with JNK and phosphorylated tau proteins A pathologic hallmark of AD is the accumulation of neurofibrillary tangles. We evaluated whether IB1/JIP-1 is equally present in AD lesions. A double immunohistochemistry was performed using an affinity-purified rabbit anti-IB1/JIP-1 antibody and a monoclonal antibody directed against phosphorylated tau proteins. Immunodetection was performed using anti-rabbit IG conjugated to Texas red and an anti-mouse IG conjugated to Oregon green. As shown in Figure 1 , IB1/JIP-1 is highly expressed in neurofibrillary tangles and colocalizes with phosphorylated tau proteins. Colocalization of IB1/JIP-1 was also observed with JNK (data not shown).
Identification of a -499A4G polymorphism in the promoter region of the MAPK8IP1 gene encoding IB1/ JIP-1 and its association with human AD Nucleic acid sequences of the 5 0 regulatory region of the MAPK8IP1 obtained from 46 genomic DNA patients were aligned with the published wild-type sequence, and this allowed the detection of an A-to G-transition in the position -499 bp of the transcription initiation site within the 5 0 regulatory region of the MAPK8IP1 gene. In the 23 bp of the sequence surrounding the variant, by computer analysis (http:// bioinformatics.weizmann.ac.il/transfac/), we did not find any evidence for consensus binding site with high stringency. The variant was used as a polymorphic marker in three populations.
Study 1
A total of 230 demented individuals (46 men/184 women, age 8478 years) and 250 controls (81 men/ 169 women, age 7978 years) were selected from the ELDNOR population. Among the 230 subjects classified as demented, 71 suffered from AD (12 men/59 women, age 8476 years). To this population were added 172 AD cases (74 men/98 women, age 7078 years, 65.7% onset at or over 65 years) recruited in European countries. Between the two AD groups, there was no statistically significant difference in genotype and allele frequencies for MAPK8IP1 and LRP polymorphisms. We thus pooled the two AD populations, and study 1 consisted of the 250 controls described above compared to 243 AD patients (86 men/157 women, age 74710 years). Genotype distributions, reported in Tables 1 and 2 , are in HardyWeinberg equilibrium. There was no significant statistical differences in genotype or allele distributions according to cognitive status for either polymorphism. As expected, the presence of an APOE e4 allele is a risk factor of AD in this population (OR 4.7 (95% CI, 3.2-7.1), Po0.0001). After adjustment for age, gender and APOE status, subjects bearing at least one G allele of the MAPK8IP1 polymorphism were at higher risk of AD (OR 1.8 (95% CI, 1.0-3.5), P ¼ 0.045). When stratifying the population according to the presence or absence of the LRP exon 3 T allele (Table 3) , a statistically significant association was observed between the MAPK8IP1 polymorphism and the risk of AD (after adjustment OR 2.5 (95% CI, 1.2-5.2), P ¼ 0.016) in CC subjects. The MAPK8IP1 polymorphism was not associated with AD in subjects bearing at least one T allele.
Study 2
Study 2 was composed of 56 AD patients recruited in the long-term care department of gerontology of the hospital of Limeil-Brévannes (France) (11 men/45 women, age 8576 years) compared to 180 neuropathologically defined controls recruited at the Hospices Civils de Strasbourg (France) (89 men/91 women, age 7976 years). Genotype. and allele frequencies for MAPK8IP1 and LRP polymorphisms are reported in Tables 1 and 2 , respectively. Genotype distributions are in HardyWeinberg equilibrium. There was no significant statistical difference in genotype or allele distributions according to cognitive status for either polymorphism. The only risk factor for dementia was the APOE e4 allele (OR 5.8 (95% CI, 2.7-12.6), Po0.0001).
When stratifying the population according to the presence or absence of the LRP exon 3 T allele (Table 3) , a trend for association was observed between the MAPK8IP1 polymorphism and the risk of AD patients (OR 2.3 (95% CI, 0.8-7.2), P ¼ 0.14) in CC subjects. The MAPK8IP1 polymorphism was not associated with AD in subjects bearing at least one T allele. 
Meta-analysis
We further pooled the two studies in order to have higher statistical power, giving a population consisting of 299 AD patients (age 76710 years) and 430 controls (age 7977 years). Genotype and allele frequencies for MAPK8IP1 and LRP polymorphisms are reported in Tables 1 and 2 , respectively. As observed previously, the only one risk factor for AD was the APOE e4 allele (OR 5.0 (95% CI, 3.6-6.9), Po0.0001), a trend for association between the MAPK8IP1 polymorphism and the risk of AD (OR 1.7 (95% CI, 1.1-2.8), P ¼ 0.03). When stratifying the population according to the presence or absence of the LRP exon 3 T allele (Table 3) , a significant association was observed between the MAPK8IP1 polymorphism and the risk of AD (OR 2.1 (95% CI, 1.2-3.7), P ¼ 0.01) in CC subjects after adjustment for confounding variables.
In neuronal cells, the -499A4G results in an increased transcriptional activity of the MAPK8IP1 promoter The functional consequence of the -499A4G polymorphism was evaluated using a fragment of the human 5 0 regulatory region of the MAPK8IP1 gene recently identified. 36 The A was substituted to G in the -691/ þ 41 bp of the human promoter sequence fused to a luciferase reporter gene at the position -499 bp upstream the transcription initiation site. The wild-type promoter (WTluc, A insertion) was compared to the mutated promoter (Mutluc, G insertion). This 5 0 regulatory region was previously shown to drive high transcriptional activity in insulin-secreting cell lines. 36 Herein, the wild-type and mutated constructs were transfected into two neuroblastoma cell lines (LA-N1 and SK-N-BE) together with a vector encoding renilla for normalization. As shown in Figure 2 , the -691/ þ 41 bp of the human promoter of IB1/JIP-1 drove high transcriptional activity in LA-N1 and SK-N-BE cell lines compared to the promoterless luciferase vector. In the same cell lines, the G Figure 2 The A to G substitution (À499A4G) in the promoter of the MAPK8IP1 gene increased transcriptional activity. The -691/ þ 41 bp of the human MAPK8IP1 promoter was fused to a luciferase reporter gene. This construct (IB1WTluc) drove high transcriptional activity in two neuroblastoma cell lines (LA-N1 and SK-N-BE) in comparison to the promoterless vector. The A to G substitution (IB1mutLUC) induced a 46 and 16% increase in transcriptional activity compared to the IB1WTluc construct in La-N1 and SK-N-BE, respectively. Luciferase activities were normalized using pRLCMV renilla, and the results are expressed as mean 7 SEM. RLU: relative light units. **Po 0.01, *Po 0.05.
IB1/JIP-1 and Alzheimer's disease N Helbecque et al substitution of the promoter drove higher transcriptional activity compared to the wild-type promoter (41 and 16% increase for the MUTLUC compared to the WTLUC in LA-N1 and SK-N-BE cells, respectively; Po0.01 and o0.05).
The -499A4G polymorphism increased the DNAbinding activity of the MAPK8IP1 promoter To assess whether the increase of transcriptional activity of the MAPK8IP1 variant was due to an increased or a reduced DNA-binding activity, we performed several EMSA using nuclear extracts prepared from LA-N1 cells. As shown in Figure 3a , a specific binding pattern was detected when nuclear extracts were incubated in the presence of the labelled wild-type cis-element (WT h-499). The specificity of the DNA-binding activity was then evaluated by competition using an excess of cold mutated (MUT h-499) or wild-type (WT h-499) oligonucleotides. In Figure 3a , the binding pattern observed using the wild-type sequence as the labelled probe is more pronounced in a competition assay by Figure 3 Binding activity of the 23 bp sequence covering the -499A4G polymorphism of MAPK8IP1. (a) EMSA was performed using nuclear extracts from LA-N1 cells incubated with the wild-type (WT h-499) labelled probe. A binding pattern is observed (arrowheads) compared to the free-probe migration. This pattern is better competed by adding a 100-or 500-fold molar excess of unlabelled mutated (MUT h-499) probe compared to wild-type (WT h-499) sequence. This experiment was performed three times. NS; nonspecific competitor. (b) Quantitative assessment of the competition assays (100-, 500-, and 1000-fold excess) was measured by densitometric scanning. the 100-and 500-fold molar excesses of the MUT h-499 sequence were significantly better competitors compared to the WT h-499 probe. Graphs are expressed as means.7SEM (n ¼ 3, *Po0.05).
using an excess of 100-or 500-fold of the cold MUT h-499 compared to WT h-499. These data indicate that the binding affinity of the nuclear protein to the mutated oligonucleotides was more pronounced than the one observed with the wild-type oligonucleotides. Conversely, we used as labelled cis-element, the mutated oligonucleotides (MUT h-499). The binding pattern to the MUT h-499 is similar to the one observed with the labelled WT h-499 (data not shown). A quantitative assessment of the competition assays is depicted in Figure 3b . In summary, the A to G substitution is located in a regulatory element of the promoter of the MAPK8IP1 gene. The G substitution is associated with an increase in transcriptional activity compared to the wild-type promoter and an enhanced binding activity detected by EMSA using nuclear extracts prepared from a neuronal cell line compared to the wild-type cis-element.
Discussion
Herein we describe an A to G substitution at position -499 of the promoter region of the MAPK8IP1 gene encoding IB1/JIP-1. In neuronal cells, this variant increased the transcriptional activity of the MAP-K8IP1 promoter, suggesting that this variant is located within a critical cis-regulatory region. By mobility shift assay, we confirmed that the nucleotides surrounding the -499A4G act as DNA-binding region to neuronal nuclear extracts and are also associated with an increased binding activity. These data indicate that the À499A4G increases the transcriptional activity of the MAPK8IP1 gene. The functional consequences of an increase in IB1/ JIP-1 content in neuronal cells may be anticipated upon several observations. In vitro and in vivo, modulation of IB1/JIP-1 content in a cell can have profound effects on several signalling pathways. The selective disruption of IB1/JIP-1 in mice is associated with a loss of signalling mediated by activated JNK in neuronal cells and with a resistance to proapoptotic stimuli. 11 In another mice strain, the complete knockout was associated with early embryological death while haploinsufficient IB1/JIP-1 7 mice were more vulnerable to proapoptotic stimuli 12 (F. Magara et al, submitted). These in vivo observations were corroborated in vitro in different cell models. The exposure of insulin-secreting cells to various stimuli such as cytokines, starving or UV induced a reduction in IB1/JIP-1 content which is associated with an increased JNK activity and accelerated apoptosis. 28 This signal transduction could be prevented by overexpressing IB1/JIP-1.
5, 9,10,28,31 A modest increase in IB1/JIP-1 content is probably not associated with a protective effect upon proapoptotic signals and may also modify the stoichiometry of some interactions of IB1/JIP-1 with critical cellular partners such as APP, kinesin or JNK.
In rodents, IB1/JIP-1 was shown to be highly expressed in neuronal cells, in particular in the hippocampus, the cortex and the cerebellum. [25] [26] [27] In this study, we extended these observations by demonstrating the presence of IB1/JIP-1 in human AD brain colocalized with JNK and phosphorylated tau proteins in neurofibrillary tangles. IB1/JIP-1 interacts with many cellular components including the reelin receptor ApoER2, LRP, a-synuclein, 190 RhoGEF, kinesin and APP [13] [14] [15] [16] [17] [18] 40 . In mice, the selective disruption of both ApoER2 and VLDL receptor (VLDLR) induced a drastic phenotype associated with abnormal neuronal migration and development. 41 These data indicated that lipoprotein receptors are not only able to interact with various lipoproteins including ApoE and facilitate lipid uptake within a cell but are also able to transduce a cellular signal. 23, 42, 43 The cellular components involved in this signalling pathway include APP, DAB1 and IB1/ JIP-1. LRP and the VLDLR were studied as candidate genes to AD and were inconsistently associated with AD. [20] [21] [22] 44 Herein we found that the þ 766C4T polymorphism of exon 3 of the LRP gene was not associated, when analysed alone, with an increased risk of AD (OR 1.2 (95% CI, 0.9-1.8), P ¼ 0.24) although a metaanalysis of all previous works indicated a modest association between the CC genotype and AD (OR 1.35 (95% CI, 1.1-1.7), P ¼ 0.01). 45 We also found a trend for association between the A to G substitution of MAPK8IP1 and an increased risk of AD when the two studies were pooled together, and the association in early-onset AD should be only a chance result. The IB1/JIP-1 polymorphism becomes a significant risk of AD in subjects bearing the CC genotype in exon 3 of the LRP gene (OR 2.1 (95% CI, 1.2-3.7), P ¼ 0.01), suggesting a possible additive effect of these two gene variants in the risk of AD. Similar additive effects were described previously where the -3826A4G variant of the uncoupling protein gene was shown to interact with the b3-adrenergic receptor gene in the onset of obesity or with a polymorphism of the CRH gene in interaction with a polymorphism of the glucocorticoid-receptor gene in relation to cortisol secretion and obesity. 46, 47 The þ 766C4T transition of the LRP gene is a silent nucleotide substitution located in the NH 2 -terminal part of the protein. In vivo, the CC genotype is associated with a reduced LRP expression, negatively impacting clearance of the beta-amyloid peptide, and with a lower age at onset among AD cases. 48 These findings could explain, at least in part, why the observed effect was more significant in early-onset subjects in study 3. It could be hypothesized that another functional variant is in linkage disequilibrium with the þ 766C4T polymorphism which potentiates, in a additive manner, the effect of the IB1/JIP-1 polymorphism. Since LRP interacts with IB1/JIP-1, it is conceivable that an unknown mutation located in the vicinity of the LRP gene can alter the interaction betwen LRP and IB1/JIP-1. Further work will be required to evaluate whether the þ 766C4T polymorphism could be in linkage desiquilibrium with a mutation located in the carboxy-terminal part IB1/JIP-1 and Alzheimer's disease N Helbecque et al of the LRP gene or nearby the LRP locus. Herz and Howell suggested that these protein-protein interactions are critical to initiate a cellular signalling information. 42, 43 Our study extends this observation since both polymorphisms of the LRP and the IB1/JIP-1 may interact as a risk factor to AD. The identification of an IB1/JIP-1 functional polymorphism associated with AD is potentially important from a therapeutical standpoint. Recently, new chemically derived molecules were generated that are potent inhibitor of the JNK-activated pathway. 49 Furthermore, small modified peptides (JKIs) were also designed to enter the cell and inhibit the interaction of IB1/JIP-1 with other cellular components. 29, 30 These tools may represent, at least theoretically, potent pharmaceutical modulators to increase neuronal cell survival and modify the course of AD.
In conclusion, we propose that the -499A4G polymorphism, which increased the transcriptional activity of the MAPK8IP1 gene, contributes, in interaction with the LRP gene, to the onset of AD.
